SMARCB1 and epithelioid sarcoma: While several clinical trials are testing these potential dependencies in patients, early in 2020 the EZH2i tazemetostat received for the first time FDA approval for the treatment of epithelioid sarcomas with SMARCB1/INI1 deletions.